This is an extended update that I’ve been planning to write for some time, however, there was always some shiny new clinical data to highlight and discuss so it sadly stayed on the backburner!
Over the next few weeks, we will post some meaty reviews on various topics pertinent to cancer research R&D. They might involve a particular tumour type that is seeing extensive developments, an important or difficult target, or even a particular category approach, for example.
In the first of this new mini-series, we take a look at the CAR-T cell therapy niche and highlight some important new developments that are well worth watching out for.
Things are a-changin’ very rapidly here, including numerous R&D threats from the east (China) so it’s a good opportunity to take stock and look forward.
Here we go – hold on to your hats…